Related Experiment Video
Updated: May 28, 2026
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
Melittin attenuates liver injury in thioacetamide-treated mice through modulating inflammation and fibrogenesis
Ji-Hyun Park1, Yoon-Seup Kum, Tae-Im Lee
1Department of Pathology, Catholic University of Daegu, College of Medicine, 3056–6 Daemyung 4-Dong, Nam-Gu, Daegu 705–718, Republic of Korea.
Abstract:
Liver fibrosis represents a process of healing and scarring in response to chronic liver injury. Following injury, an acute inflammation response takes place resulting in moderate cell necrosis and extracellular matrix damage. Melittin, the major bioactive component in the venom of honey bee Apis mellifera, is a 26-residue amphipathic peptide with well-known cytolytic, antimicrobial and proinflammatory properties. However, the molecular mechanisms responsible for the anti-inflammatory activity of melittin have not been elucidated in liver fibrosis. We investigated whether melittin ameliorates liver inflammation and fibrosis in thioacetamide (TAA)-induced liver fibrosis. Two groups of mice were treated with TAA (200 mg/L, in drinking water), one of the groups of mice was co-treated with melittin (0.1 mg/kg) for 12 weeks while the other was not. Hepatic stellate cells (HSCs) were cultured with tumor necrosis factor α in the absence or presence of melittin. Melittin suppresses the expression of proinflammatory cytokines through the nuclear factor (NF)-κB signaling pathway. Moreover, melittin reduces the activity of HSCs in vitro, and decreases the expression of fibrotic gene responses in TAA-induced liver fibrosis. Taken together, melittin prevents TAA-induced liver fibrosis by inhibiting liver inflammation and fibrosis, the mechanism of which is the interruption of the NF-κB signaling pathway. These results suggest that melittin could be an effective agent for preventing liver fibrosis.
Insights
Melittin, from bee venom, effectively reduces liver inflammation and fibrosis in mice by blocking the NF-κB pathway. This suggests melittin as a potential therapeutic agent for preventing liver scarring.
Area of Science:
- Hepatology
- Immunology
- Pharmacology
Background:
- Liver fibrosis results from chronic injury and inflammation, leading to scarring.
- Melittin, a bee venom peptide, has known anti-inflammatory properties, but its role in liver fibrosis is unclear.
- Understanding melittin's mechanism in liver fibrosis is crucial for therapeutic development.
Purpose of the Study:
- To investigate melittin's efficacy in ameliorating thioacetamide (TAA)-induced liver inflammation and fibrosis.
- To elucidate the molecular mechanisms underlying melittin's anti-inflammatory and anti-fibrotic effects in the liver.
- To assess melittin's impact on hepatic stellate cell (HSC) activity and fibrotic gene expression.
Main Methods:
- Mice were subjected to thioacetamide (TAA)-induced liver fibrosis.
- Experimental groups received either TAA alone or TAA co-treated with melittin.
- In vitro studies involved culturing hepatic stellate cells (HSCs) with tumor necrosis factor α and melittin.
Main Results:
- Melittin significantly suppressed the expression of pro-inflammatory cytokines via the nuclear factor (NF)-κB signaling pathway.
- Melittin reduced hepatic stellate cell (HSC) activity in vitro.
- Melittin decreased the expression of fibrotic genes in TAA-induced liver fibrosis models.
Conclusions:
- Melittin effectively prevents TAA-induced liver fibrosis by inhibiting inflammation and fibrosis.
- The mechanism involves the interruption of the NF-κB signaling pathway.
- Melittin shows promise as a potential therapeutic agent for preventing liver fibrosis.
